Vyxeos Injection Improves Overall Survival in Phase III Acute Myeloid Leukemia Trial

Researchers discover gene that could help improve treatment decisions in childhood leukemia

A new type of cancer cell that “warrants urgent investigation” has been discovered in childhood leukaemia, and could impact clinical care. Research into new or repurposed treatments that target this new cell type could give hope to children and families worldwide.

November 14, 2025

Vol.51 No.42

Drugs & Targets

FDA approves Komzifti for r/r NPM1-mutated AML

FDA has granted full approval of Komzifti (ziftomenib) for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation who have no satisfactory alternative treatment options. Komzifti is the first and only once-daily, oral menin inhibitor approved for R/R NPM1-mutated AML, a devastating blood cancer with limited treatment options.

November 14, 2025

Vol.51 No.42

Clinical Roundup

Study assesses cancers in children exposed to medical imaging

Ten percent of pediatric blood and bone marrow cancers may have stemmed from radiation exposure, according to a study led by UC San Francisco and UC Davis.

September 26, 2025

Vol.51 No.35

Clinical Roundup

Outpatient administration of CAR T-cell therapy shows promising outcomes for lymphoma

The ZUMA-24 phase II clinical trial demonstrates the safety and feasibility of administering Yescarta (axi-cel) in the outpatient setting when treating relapsed or refractory large B-cell lymphoma.

September 19, 2025

Vol.51 No.34

Clinical Roundup

WashU Medicine genetic study suggests ways to catch blood cancer earlier

Acquired mutations in blood stem cells—whether arising from smoking, exposure to toxins or even normal aging—interact with mutations passed down by parents in important ways that influence a person’s lifetime risk of developing blood cancer, a study led by researchers at WashU Medicine found.

September 12, 2025

Vol.51 No.33

Clinical Roundup

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

EPCORE FL-1 phase III trial results show that subcutaneous epcoritamab in combination with rituximab and lenalidomide reduced the risk of disease progression or death by 79% for patients with relapsed/refractory follicular lymphoma.

August 08, 2025

Vol.51 No.31

Vyxeos Injection Improves Overall Survival in Phase III Acute Myeloid Leukemia Trial

YOU MAY BE INTERESTED IN

Researchers discover gene that could help improve treatment decisions in childhood leukemia

FDA approves Komzifti for r/r NPM1-mutated AML

Study assesses cancers in children exposed to medical imaging

Outpatient administration of CAR T-cell therapy shows promising outcomes for lymphoma

WashU Medicine genetic study suggests ways to catch blood cancer earlier

In phase III trial, epcoritamab regimen improves PFS in R/R follicular lymphoma

Renew today!

Subscriber content

Never miss an issue!

Login